Fair-treatment and consumer-protection rules for patients and clinicians

Why the ban exists: the approval only covers the uses that were actually tested and reviewed. Promoting beyond that pushes products into unproven territory, which is exactly what drives consumer-protection enforcement.

Concrete example: a company markets an insulin pump cleared for adults. A sales rep tells a paediatric clinic it "works great for kids too." That is off-label promotion, even if some doctors already use it that way.

In the US this is enforced through the Food, Drug, and Cosmetic Act and the False Claims Act, the latter of which powers those multibillion-dollar settlements. In Europe, national authorities and the EMA (European Medicines Agency) framework apply, with member states enforcing.

Note a nuance developed through US court cases (for example *Amarin v. FDA*, 2015): truthful, non-misleading scientific information can sometimes be shared even when it touches unapproved uses. The safe zone is narrow, and marketers should treat it as legal territory, not a green light.

Balanced risk disclosure: fair balance

You cannot advertise benefits while burying risks. In US drug DTC advertising this is called fair balance: risk information must be presented with a scope and prominence comparable to the benefit claims.

This is why US TV drug ads spend long seconds listing side effects. It is not decoration; it is a regulatory requirement.

For a home-use device aimed at consumers, fair balance means plain language. A continuous glucose monitor ad cannot just show a smiling user. It must communicate limitations: readings may lag actual blood glucose, and users should confirm with a fingerstick before treatment decisions in certain situations.

The FDA publishes accessible guidance on this. See the FDA's Bad Ad program overview, which trains clinicians to spot misleading promotion.

The rule scales with the audience

For a professional audience, "balance" can be dense clinical data: hazard ratios, adverse event rates, contraindications in a package insert. A cardiologist is expected to interpret it.

For a consumer, the same balance must be readable at roughly an eighth-grade level, with risks that a non-expert can actually act on. Same drug, same evidence, two completely different creative executions.

Vulnerable-patient safeguards

Some audiences get extra protection because they are less able to assess claims or resist persuasion: children, the elderly, the seriously ill, the cognitively impaired, and people in acute distress.

Practical implications for marketers:

• Children: stricter limits on direct appeals. Marketing a device for paediatric diabetes typically targets parents and clinicians, not kids.
• Serious or terminal illness: claims cannot exploit desperation. Oncology messaging is scrutinised hard for implying false hope or overstated survival benefit.
• Cognitive vulnerability: for Alzheimer's or mental health products, regulators watch for messaging that pressures caregivers.

Example contrast from the hook: marketing a home glucose test to a person newly diagnosed with diabetes (a potentially anxious consumer) demands simple, non-alarming, risk-balanced language. Marketing a surgical implant to a surgeon can be technical and comparative, because the professional is the decision-maker and the patient is protected by that professional's judgment.

Medical devices are not drugs

Device marketing follows a related but separate track.

In the US, devices are regulated by the FDA under classes I, II, and III (rising by risk). Class III includes implantable devices like pacemakers. Marketing claims must match the cleared or approved intended use.

In Europe, the Medical Device Regulation (MDR) 2017/745, fully applied since 2021, tightened claim rules significantly. Article 7 of the MDR explicitly prohibits misleading claims: you cannot ascribe functions the device does not have, create false impressionsimpressionsThe total number of times an ad or piece of content is displayed, regardless of clicks. Each display counts as one impression, even to the same person.View full definition → about treatment, or fail to inform users of likely risks. This applies to advertising aimed at both consumers and professionals.

Pre-launch marketing compliance checks

Before a single ad runs, biotech and medtech companies route promotional materials through a formal review. Getting this wrong is expensive and slow, so marketers build it into timelines from day one.

The MLR review

Most pharma and larger medtech firms use MLR review: Medical, Legal, and Regulatory. Every promotional piece (a brochure, a website, a conference booth panel, a social post) is reviewed by:

• Medical/Scientific: does every claim have solid data behind it?
• Legal: does it comply with law and avoid false-claims exposure?
• Regulatory: does it stay inside the approved label and required disclosures?

Nothing ships until all three sign off. A common junior-marketer mistake: designing a beautiful campaign, then discovering MLR strips out the strongest headline because the data does not support it.

Claims substantiation

Every benefit claim needs evidence tied to it, usually documented in a claims matrix: a simple table mapping each marketing statement to its supporting source.

| Marketing claim | Supporting evidence | Approved? |

|---|---|---|

| "Reduces fingersticks" | Pivotal trial, primary endpoint | Yes |

| "Most accurate monitor" | No head-to-head data | No, remove |

| "Cleared for adults 18+" | FDA clearance letter | Yes |

If a claim has no row in the matrix, it does not run.

US submission mechanics

For US prescription drug promotion, companies submit promotional materials to the FDA's OPDP (Office of Prescription Drug Promotion) using Form FDA 2253 at the time of first use. OPDP can issue untitled letters (a warning) or warning letters (serious) demanding corrections and sometimes corrective advertising. These letters are public, so a violation becomes a reputational event, not just a legal one.

Europe: often self-regulated, still binding

In Europe, industry codes do heavy lifting. Bodies like the ABPI (Association of the British Pharmaceutical Industry) in the UK and EFPIA (European Federation of Pharmaceutical Industries and Associations) at EU level run codes of practice that members must follow. Breaches lead to rulings, fines, and published censure. Combined with MDR and national law, the practical result is strict pre-clearance in most markets.

Putting it together

Return to our two people. The diabetic at the kitchen table gets simple language, honest limitations, no exploitation of new-diagnosis anxiety, and no claim beyond what the device is cleared to do. The surgeon choosing an implant gets full clinical data, comparative evidence within the approved use, and MDR-compliant claims, because the professional carries the interpretive burden.

Same company, same portfolio, radically different marketing, all driven by fair-treatment and consumer-protection rules.

Key Takeaways

• Audience determines the rules. DTC (consumer) messaging is tightly controlled and, for prescription drugs, banned in most of Europe; professional promotion can be technical but must stay truthful and on-label.
• Never promote off-label. Doctors may prescribe off-label; companies promoting it face False Claims Act exposure and settlements that have run into billions.
• Fair balance is mandatory. Benefits and risks must be presented with comparable prominence, scaled to the audience's ability to understand.
• Protect vulnerable patients. Children, the seriously ill, and the cognitively impaired trigger stricter limits; never exploit fear or false hope.
• Build compliance in early. Run every asset through MLR review with a claims matrix, file US materials on Form FDA 2253, and respect EU MDR Article 7 and industry codes before launch, not after.